Clinical Trial

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-21; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT07145190
Lead Sponsor Bial - Portela C S.A.
Conditions Parkinson Disease
Enrollment 90 participants
Start Date 2025-08-27
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-11